MY209775A - Compositions and methods for treating and preventing amyotrophic lateral sclerosis - Google Patents
Compositions and methods for treating and preventing amyotrophic lateral sclerosisInfo
- Publication number
- MY209775A MY209775A MYPI2021003225A MYPI2021003225A MY209775A MY 209775 A MY209775 A MY 209775A MY PI2021003225 A MYPI2021003225 A MY PI2021003225A MY PI2021003225 A MYPI2021003225 A MY PI2021003225A MY 209775 A MY209775 A MY 209775A
- Authority
- MY
- Malaysia
- Prior art keywords
- lateral sclerosis
- amyotrophic lateral
- compositions
- treating
- methods
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/0004—Oxidoreductases (1.)
- C12N9/0089—Oxidoreductases (1.) acting on superoxide as acceptor (1.15)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/321—2'-O-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/322—2'-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/33—Chemical structure of the base
- C12N2310/334—Modified C
- C12N2310/3341—5-Methylcytosine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/352—Nature of the modification linked to the nucleic acid via a carbon atom
- C12N2310/3525—MOE, methoxyethoxy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/32—Special delivery means, e.g. tissue-specific
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/35—Special therapeutic applications based on a specific dosage / administration regimen
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y115/00—Oxidoreductases acting on superoxide as acceptor (1.15)
- C12Y115/01—Oxidoreductases acting on superoxide as acceptor (1.15) with NAD or NADP as acceptor (1.15.1)
- C12Y115/01001—Superoxide dismutase (1.15.1.1)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Virology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Enzymes And Modification Thereof (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862779916P | 2018-12-14 | 2018-12-14 | |
| US201962807603P | 2019-02-19 | 2019-02-19 | |
| US201962840879P | 2019-04-30 | 2019-04-30 | |
| PCT/US2019/065936 WO2020123783A1 (en) | 2018-12-14 | 2019-12-12 | Compositions and methods for treating and preventing amyotrophic lateral sclerosis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MY209775A true MY209775A (en) | 2025-08-03 |
Family
ID=69160351
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MYPI2021003225A MY209775A (en) | 2018-12-14 | 2019-12-12 | Compositions and methods for treating and preventing amyotrophic lateral sclerosis |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US20220073930A1 (https=) |
| EP (1) | EP3894557A1 (https=) |
| JP (2) | JP7612575B2 (https=) |
| KR (2) | KR20250090384A (https=) |
| CN (3) | CN118987017A (https=) |
| AU (1) | AU2019396522B2 (https=) |
| BR (1) | BR112021011334A2 (https=) |
| CA (1) | CA3115549A1 (https=) |
| CL (1) | CL2021001136A1 (https=) |
| CO (1) | CO2021008187A2 (https=) |
| CR (1) | CR20210384A (https=) |
| IL (1) | IL283833A (https=) |
| JO (1) | JOP20210143A1 (https=) |
| MX (1) | MX2021005086A (https=) |
| MY (1) | MY209775A (https=) |
| PH (1) | PH12021551365A1 (https=) |
| SG (1) | SG11202103415WA (https=) |
| TW (1) | TWI906204B (https=) |
| UY (1) | UY38506A (https=) |
| WO (1) | WO2020123783A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10436802B2 (en) | 2014-09-12 | 2019-10-08 | Biogen Ma Inc. | Methods for treating spinal muscular atrophy |
| CN119679944A (zh) | 2018-01-25 | 2025-03-25 | 渤健马萨诸塞州股份有限公司 | 治疗脊髓性肌萎缩症的方法 |
| US12429487B2 (en) | 2018-12-06 | 2025-09-30 | Biogen Ma Inc. | Neurofilament protein for guiding therapeutic intervention in amyotrophic lateral sclerosis |
| BR112023019877A2 (pt) * | 2021-03-31 | 2023-11-07 | Biogen Ma Inc | Tratamento de esclerose lateral amiotrófica |
| WO2025045130A1 (zh) * | 2023-08-29 | 2025-03-06 | 石药集团中奇制药技术（石家庄）有限公司 | 一种抑制sod1基因表达的dsrna分子及其应用 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2452458A1 (en) | 2001-07-03 | 2003-01-16 | Isis Pharmaceuticals, Inc. | Nuclease resistant chimeric oligonucleotides |
| WO2013134403A1 (en) * | 2012-03-06 | 2013-09-12 | The Washington University | Method of treating neurodegenerative diseases with microrna regulators |
| EP3119888B1 (en) * | 2014-03-19 | 2021-07-28 | Ionis Pharmaceuticals, Inc. | Compositions for modulating ataxin 2 expression |
| HUE050704T2 (hu) * | 2014-04-01 | 2020-12-28 | Biogen Ma Inc | Összetételek a SOD-1 expressziójának modulálására |
| WO2016077687A1 (en) * | 2014-11-14 | 2016-05-19 | Voyager Therapeutics, Inc. | Compositions and methods of treating amyotrophic lateral sclerosis (als) |
| JP2020518258A (ja) * | 2017-05-05 | 2020-06-25 | ボイジャー セラピューティクス インコーポレイテッドＶｏｙａｇｅｒ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． | 筋萎縮性側索硬化症（ａｌｓ）治療組成物および方法 |
| WO2018218219A1 (en) * | 2017-05-26 | 2018-11-29 | University Of Miami | Determining onset of amyotrophic lateral sclerosis |
-
2019
- 2019-12-06 TW TW108144617A patent/TWI906204B/zh active
- 2019-12-11 UY UY0001038506A patent/UY38506A/es not_active Application Discontinuation
- 2019-12-12 JP JP2021525191A patent/JP7612575B2/ja active Active
- 2019-12-12 EP EP19836331.9A patent/EP3894557A1/en active Pending
- 2019-12-12 MX MX2021005086A patent/MX2021005086A/es unknown
- 2019-12-12 CR CR20210384A patent/CR20210384A/es unknown
- 2019-12-12 CA CA3115549A patent/CA3115549A1/en active Pending
- 2019-12-12 MY MYPI2021003225A patent/MY209775A/en unknown
- 2019-12-12 CN CN202411184883.6A patent/CN118987017A/zh active Pending
- 2019-12-12 SG SG11202103415WA patent/SG11202103415WA/en unknown
- 2019-12-12 KR KR1020257019188A patent/KR20250090384A/ko active Pending
- 2019-12-12 US US17/291,199 patent/US20220073930A1/en active Pending
- 2019-12-12 AU AU2019396522A patent/AU2019396522B2/en active Active
- 2019-12-12 WO PCT/US2019/065936 patent/WO2020123783A1/en not_active Ceased
- 2019-12-12 KR KR1020217020529A patent/KR102821047B1/ko active Active
- 2019-12-12 CN CN201980080996.2A patent/CN113330116A/zh active Pending
- 2019-12-12 CN CN202411184930.7A patent/CN119185345A/zh active Pending
- 2019-12-12 BR BR112021011334-7A patent/BR112021011334A2/pt unknown
-
2021
- 2021-04-29 CL CL2021001136A patent/CL2021001136A1/es unknown
- 2021-06-09 IL IL283833A patent/IL283833A/en unknown
- 2021-06-09 PH PH12021551365A patent/PH12021551365A1/en unknown
- 2021-06-09 JO JOP/2021/0143A patent/JOP20210143A1/ar unknown
- 2021-06-23 CO CONC2021/0008187A patent/CO2021008187A2/es unknown
-
2024
- 2024-12-06 JP JP2024213950A patent/JP2025023319A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20220073930A1 (en) | 2022-03-10 |
| KR20210131992A (ko) | 2021-11-03 |
| MX2021005086A (es) | 2021-08-16 |
| KR20250090384A (ko) | 2025-06-19 |
| TWI906204B (zh) | 2025-12-01 |
| EP3894557A1 (en) | 2021-10-20 |
| JOP20210143A1 (ar) | 2023-01-30 |
| CN118987017A (zh) | 2024-11-22 |
| UY38506A (es) | 2020-06-30 |
| CN113330116A (zh) | 2021-08-31 |
| JP7612575B2 (ja) | 2025-01-14 |
| TW202035694A (zh) | 2020-10-01 |
| BR112021011334A2 (pt) | 2021-09-08 |
| CA3115549A1 (en) | 2020-06-18 |
| CN119185345A (zh) | 2024-12-27 |
| KR102821047B1 (ko) | 2025-06-16 |
| CL2021001136A1 (es) | 2022-01-14 |
| AU2019396522B2 (en) | 2026-04-09 |
| JP2022513597A (ja) | 2022-02-09 |
| CR20210384A (es) | 2021-12-20 |
| SG11202103415WA (en) | 2021-06-29 |
| IL283833A (en) | 2021-07-29 |
| CO2021008187A2 (es) | 2021-09-09 |
| JP2025023319A (ja) | 2025-02-14 |
| WO2020123783A1 (en) | 2020-06-18 |
| PH12021551365A1 (en) | 2021-11-22 |
| AU2019396522A1 (en) | 2021-05-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MY209775A (en) | Compositions and methods for treating and preventing amyotrophic lateral sclerosis | |
| CR20210383A (es) | Inhibidores de apol 1 y sus métodos de uso | |
| MX2021000071A (es) | Uso de pridopidina para mejorar la funcion cognitiva y para tratamiento de enfermedad de alzheimer. | |
| GEP20227443B (en) | Magl inhibitors | |
| MY200200A (en) | Cd73 inhibitors | |
| MY195432A (en) | Methods For Inhibiting Angiogenesis In A Subject In Need Thereof | |
| EA202190581A1 (ru) | Антисмысловые олигонуклеотиды, нацеленные на scn2a, для лечения энцефалопатии scn1a | |
| MX2017015574A (es) | Inhibidores de tirosina quinasa de bruton. | |
| JOP20200035A1 (ar) | تركيبات حمض أميني لعلاج الإصابات العصبية | |
| WO2019157495A3 (en) | Methods for preventing and/or treating bone loss conditions by modulating irisin | |
| PT3952880T (pt) | 2-(2,6-dioxopiperidin-3-il)-4-((2-fluoro-4-((3-morfolinoazetidin-1-il)metil)benzil)amino)isoindolina-1,3-diona para utilização no tratamento de linfoma não-hodgkin | |
| MX2019008124A (es) | Metodos para el tratamiento de trastornos neurologicos. | |
| MX2021001807A (es) | Combinacion de un inhibidor de histona desacetilasa y un inhibidor de proteina cinasa y uso farmaceutico de la misma. | |
| EP4585273A3 (en) | Mechanism of resistance to bet bromodomain inhibitors | |
| MX2021004755A (es) | Uso de plasma y fracciones de plasma para mejorar el dolor, la cicatrizacion de heridas y la recuperacion posoperatoria. | |
| JOP20200291A1 (ar) | معدلات التعبير عن apol1 | |
| MX2022007285A (es) | Compuestos, polimeros, dispositivos y usos de los mismos. | |
| WO2019175260A3 (en) | Modified oligonucleotides for use in treatment of tauopathies | |
| EP4279127A3 (en) | Growth differentiation factor 15 as biomarker for metformin | |
| JOP20220007A1 (ar) | طرق للعلاج أو الوقاية من ضمور العضلات النخاعي | |
| PH12021551138A1 (en) | Application of chidamide in combination with r-chop, and drug combination | |
| PH12021550121A1 (en) | Methods of treating hfpef employing dapagliflozin and compositions comprising the same | |
| ZA202002107B (en) | Use of specific sirna against protein s for the treatment of hemophilia | |
| JOP20210216A1 (ar) | علاج السرطان | |
| MX384069B (es) | Biomarcadores para una terapia combinada que comprende lenvatinib y everolimus. |